It’s Time to Look Beyond Immunosuppression for Sustained Response
Now approved in ITP for use 6 months after diagnosis1
COVID-19 has become a major public health challenge around the world.
We know that you, and your patients, are looking for answers. The American Society of Hematology (ASH) has put together a series of FREQUENTLY ASKED QUESTIONS to provide certain relevant information surrounding this novel virus and the hematologic conditions you treat.
REVOLADE is the TPO-RA proven in the most disease states1
REVOLADE is indicated for the treatment of:
Patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months
or longer from diagnosis and who are refractory to other treatments (eg, corticosteroids,
Adult patients with chronic hepatitis C virus (HCV) infection for the treatment of
thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the
initiation or limiting the ability to maintain optimal interferon-based therapy
Adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to
prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic
stem cell transplantation
TPO-RA, thrombopoietin receptor agonist.
1. REVOLADE Summary of Product Characteristics. February 2019.
2. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(3):2527-2536.
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is
intended for health care professionals outside the US. If you are a US resident, please click on the US
Residents links at the top of this page. The information on this site is not country-specific and may
contain information that is outside the approved indications in the country in which you are located.
The information on the site is not country-specific, and may
contain information that is outside the approved indications in the country in which you are
located. Please contact your local Novartis representative for the latest information
specific to your country. Please contact your local Novartis representative for local
prescribing information via https://www.novartis.com/our-company/contact-us.
IMPORTANT: The information on this website is
based on the European Summary of Product Characteristics (EU SmPC)
US HCPs & Other Country-Specific
At right is a list of the countries that host a REVOLADE website based on local label
and in a local language. They are intended for health care professionals (HCPs)
only. If you are an HCP from one of the countries listed at right, click on your
country’s link to be redirected to your country’s REVOLADE website.